Evaluation of treatment-related acute myeloid leukemia or myelodysplastic syndrome risk following standard chemotherapy versus dose-intensified chemotherapy plus granulocyte colony-stimulating factor.
Publication
, Conference
Lyman, GH; Dale, DC; Wolff, D; Culakova, E; Poniewierski, MS; Crawford, J
Published in: CANCER RESEARCH
2009
Duke Scholars
Published In
CANCER RESEARCH
ISSN
0008-5472
Publication Date
2009
Volume
69
Issue
2
Start / End Page
388S / 388S
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3101 Biochemistry and cell biology
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H., Dale, D. C., Wolff, D., Culakova, E., Poniewierski, M. S., & Crawford, J. (2009). Evaluation of treatment-related acute myeloid leukemia or myelodysplastic syndrome risk following standard chemotherapy versus dose-intensified chemotherapy plus granulocyte colony-stimulating factor. In CANCER RESEARCH (Vol. 69, pp. 388S-388S).
Lyman, G. H., D. C. Dale, D. Wolff, E. Culakova, M. S. Poniewierski, and J. Crawford. “Evaluation of treatment-related acute myeloid leukemia or myelodysplastic syndrome risk following standard chemotherapy versus dose-intensified chemotherapy plus granulocyte colony-stimulating factor.” In CANCER RESEARCH, 69:388S-388S, 2009.
Lyman GH, Dale DC, Wolff D, Culakova E, Poniewierski MS, Crawford J. Evaluation of treatment-related acute myeloid leukemia or myelodysplastic syndrome risk following standard chemotherapy versus dose-intensified chemotherapy plus granulocyte colony-stimulating factor. In: CANCER RESEARCH. 2009. p. 388S-388S.
Lyman, G. H., et al. “Evaluation of treatment-related acute myeloid leukemia or myelodysplastic syndrome risk following standard chemotherapy versus dose-intensified chemotherapy plus granulocyte colony-stimulating factor.” CANCER RESEARCH, vol. 69, no. 2, 2009, pp. 388S-388S.
Lyman GH, Dale DC, Wolff D, Culakova E, Poniewierski MS, Crawford J. Evaluation of treatment-related acute myeloid leukemia or myelodysplastic syndrome risk following standard chemotherapy versus dose-intensified chemotherapy plus granulocyte colony-stimulating factor. CANCER RESEARCH. 2009. p. 388S-388S.
Published In
CANCER RESEARCH
ISSN
0008-5472
Publication Date
2009
Volume
69
Issue
2
Start / End Page
388S / 388S
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3101 Biochemistry and cell biology
- 1112 Oncology and Carcinogenesis